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ABSTRACT 
Structure and functional study of glycans are highly challenging due to the difficulties in 
analyzing glycans and limited availability of samples for study. These limitations could be 
resolved by attaching DNA barcode to the glycan, which virtually represent glycan in further 
application, by increasing the sensitivity of detection by polymerase chain reaction (PCR), 
requiring minimal samples for analysis. Assuming bigger arena of DNA Encoded Glycan 
Libraries (DEGL) in future, we propose here a method for uniquely coding all glycans using 
computer program that can convert the structural information of glycans to DNA barcode. A 
unique and universal coding for glycans will benefit both synthesis and analysis of DEGLs. As a 
proof of principle study, a small DNA Encoded Glycan Library (DEGL) of blood and globo 
series glycan antigen and its application was demonstrated in detecting blood group and breast 
cancer from plasma. 
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1 INTRODUCTION  
Glycans are important biomolecules along with proteins, lipids, and nucleic acids. Glycans 
can be divided into three main categories: O-linked glycans, N-linked glycans and glycolipids.2 
Majority of glycans are made up of N-acetylglucosamine (GlcNAc), Glucose (Glc), Galactose 
(Gal), Mannose (Man), N-acetylneuraminic acid (Neu5Ac), Fucose (Fuc), N-acetylgalactosamine 
(GalNAc), Xylose (Xyl), Glucuronic acid (GlcA), Idose (Ido).1 
Each cell in a multicellular organism is covered with dense and complex glycans. Most 
cellular secretions and extracellular matrices are found to be high in glycans and glycosylated. It 
is even seen that an envelope of a virus that bud from an infected cell to carry the glycosylation 
pattern of the host cell.3 
Glycans and glycoconjugates play a very important role in many areas of biological 
processes including cell- cell interactions, pathogenicity, mediating immunological processes, 
stabilizing proteins and cancer.4-6 Expression patterns of glycans are highly altered in diseases like 
cancer, atherosclerosis, diabetes, retrovirus infection, thrombosis, arthritis, neurodegeneration and 
many other diseases.8 Glycan structures are the important part of the antigenic determinants during 
microbial infections to which the host immune cells recognizes and mount immune responses 
against the infection.9 For example, breast cancer can be detected by Globo-H glycan, an important 
biomarker seen in breast cancer.7 Therefore, glycans have a pivotal role in molecular recognition 
and signaling, making sugar-receptor interaction at the structural level highly necessary; and this 
interaction of polysaccharide with receptors are major  area of focus in academic and industrial 
research.8,10 
Functional Glycomics; a systematic study of the structures and functions of carbohydrates 
is yet to reach the level attained by the genomics and proteomics despite so much importance of 
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glycans. Template driven biosynthesis of DNA-RNA-Protein by nature itself also known as the 
Central Dogma Theory of Molecular Biology made the researchers apply and adopt this knowledge 
in the synthesis and analysis of these molecules. Apart from this, the easy availability of 
experimentation methods and materials for the synthesis and analysis of DNA, RNA, and proteins 
made the researchers focus on genomics and proteomics and take up those areas to what they are 
today. However, such free-flowing information is not available for carbohydrate making functional 
glycomics exceptionally challenging. Since glycans are less organized without a template driven 
machinery, it is necessary to develop a specific method for synthesis and analysis for each glycan. 
Although with the recent advancement in technology allowed the development of solid phase 
automated and enzymatic synthesis, which reduced the difficulties in obtaining the glycans, but 
the materials and experimentations are still extremely difficult and complex especially for complex 
glycans. Therefore, there is a need for a development of versatile and ultra-sensitive detection 
technology as it is of high importance in the field of carbohydrate research for detection and 
characterization of glycan-protein interaction. 
The methods now used for studying glycan-protein interaction are mainly carbohydrate 
microarrays,11,12 surface plasmon resonance,13 enzyme linked lectin assay,12 isothermal 
calorimetry,14 glycosylated conductive polymer,15 and crystallographic studies.16 In carbohydrate 
research, widely used method is microarray with carbohydrate derivatives by various means of 
immobilization technology.11,17-18 However, all the above methods have its own limitations, 
mainly because these techniques uses immobilized glycans that do not mimic the biological 
environment of binding. The detection also requires tagging of the target, glycan modifications 
and specific binding of antibodies, in addition, the interaction of glycans with targets are also very 
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weak, which makes the generation sugar library having a glycodendrimer on a slide with optimum 
distance for specific binding highly challenging. 
DNA-encoded glycan libraries (DEGL) can be considered as a potential alternative or 
adjunct to the prevailing glycan detecting techniques. DEGL adopt DNA sequences specifically 
for each glycan in the library, which enable sensitive detection by signal amplification PCR and 
identifying by DNA sequencing. For functional glycomics study, DEGL of interest is constructed 
and interacted with specific proteins. Unbound glycans are removed by washing, and bound ones 
are amplified using quantitative Polymerase Chain Reaction (qPCR), also known as real time PCR 
(RT-PCR) and sequenced to reveal identities. 
Next generation technologies in genomics extended the applications of DNA beyond 
genetics, the most prominent one being DNA encoding. The concept of DNA encoding was 
introduced in 1992, but it gained momentum recently with the advancement of Next Generation 
Sequencing (NGS) technologies.20-22 The major advantage of the technology is its efficiency in 
handling thousands of molecules with uniquely generated sequences and their high throughput 
analysis. The DNA tagging concept was initially applied in glycomics by Kwon and his coworkers, 
demonstrating Glyco-PCR, a method to detect Glycan-Binding Proteins (GBP) using DNA- 
conjugated glycan with high sensitivity. 23-24 In one of the previous work reported by Kwon and 
his coworkers, they have shown glyco-quantitative polymerase chain reaction (Glyco-qPCR) assay 
platform that allows the ultrasensitive detection and quantification of glycan in biological samples.  
They used therapeutic carbohydrates like chondroitin sulfate (a GAG), and Proteoglycans (PG) 
from Chinese hamster ovary cells (CHO) separated by capillary electrophoresis, Glycoprotein 
obtained from PNGaseF treatment of decorin core Glycoprotein (GP). They used EDC/NHS 
chemistry to covalently link the DNA tag and glycan, and unbound DNA was washed using 
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streptavidin-coated magnetic beads as the glycans they used were biotinylated. They also did a 
proof of concept study, in GAG-binding proteins, where interaction was tested between Heparin-
Antithrombin and Chondroitin-Antithrombin. With this work, they proved that glyco-qPCR can 
be used to analyze the glyco-interactome and by applying PCR amplification glycan as low as 1 
zettamoles can be detected.23     
Later on, they also demonstrated glyco-PCR in the detection of active botulinum 
neurotoxin (BoNT). They used Sialyllactose, which interacts with binding-domain of BoNTs, 
sialyllactose-DNA conjugate was used as binding-probe for active BoNT and recovered through 
BoNT-immunoprecipitation. Glyco-PCR analysis of the bound sialyllactose-DNA is then used to 
detect low attomolar concentrations of BoNT and attomolar to femtomolar concentrations of 
BoNT in honey. They also did a comparative study through the dual binding of antibodies and 
monovalent or multivalent SL-DNA conjugates to toxins.24      
But these studies were limited to certain types of glycan and there was no rationale behind 
the selection of DNA sequences. Thus, developing a general platform for the DNA encoding of 
glycans and subsequent detection has a significance role to play in the functional glycomics. In 
this work, we demonstrated three fundamental aspects of DNA encoding of glycans, a universal 
methodology for the coding of glycans based on the structure of the glycan, an easy and efficient 
chemistry for the coupling of the DNA with the glycan and finally PCR and qPCR-based methods 
for the quantitative detection of the glycans. 
1.1  Purpose of the Study 
Glycans play a very important role in many biological processes including cell- cell 
responses, pathogenicity and immune responses etc. Despite so much importance, there is still a 
need for an efficient method for detection and analyzing glycan-protein interactions in the field of 
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carbohydrate research.  Currently, carbohydrate microarray is successfully being used with the 
help of immobilization technology. But this also has its own limitations, most important one is its 
efficiency of mimicking the biological environment of the binding. Hence, we envision here 
developing a successful method for DNA-encoded Glycan Libraries (DEGLs). 
There has already been reported evidence,23-24 for demonstrating Glyco-PCR, as a method 
to detect Glycan- Binding Protein (GBP). But these studies do not have any rationale behind the 
selection of DNA tags. Our aim is to develop a broadly accepted general platform for DNA 
encoding in glycomics. This could be achieved by proper selection of DNA codes, DNA-Glycan 
conjugation by click chemistry and method of detection of DNA-Glycan conjugates using qPCR.  
This work attempted to address all three steps generating a DNA code specifically for each 
glycan by a developing a software, which could be used in future for any DEGL containing any 
specific glycans, generation of DNA tags for each element in the library by adding forward and 
reverse primer binding on each end for PCR amplification, and 5’ terminal alkyne modification to 
offer coupling with the glycan using click chemistry (CuAAC) and to develop a method of 
detection of DNA-Glycan conjugates using qPCR as a proof principle application study. 
Generating a DNA code specific for each glycan-based on its structure was attained by 
developing a software using basic computing principles in a computer language Python. The 
development and the logic underlying in generating a DNA code specific for each glycan is 
described elaborately under experiment section later. 
1.1.1 Click Chemistry 
Lack of abundant samples to play with demands a near perfect conjugation chemistry for 
the synthesis of DNA glycan conjugates. We tested few of the well-known bioorthogonal reactions 
widely used in chemical biology, glycan analysis and detection many cell surface glycans.25-26 
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Well developed bioorthogonal reactions include Staudinger Ligation, 27 Copper-catalyzed azide-
alkyne Cycloaddition (also called as CuAAC),28 strain promoted alkyne-azide cycloaddition (also 
called as Cu-free click chemistry or SPAAC).29 
 
Figure 1.1 Staudigner Ligation 
Staudinger ligation was the first bioorthogonal reaction reported by Staudinger and co-
workers in 1919.27 This is bioorthogonal ligation that transforms azides to primary amines by 
phosphines.30 Later some modifications were made to this reaction, such as using modified 
reagent. Accompanied by those changes, Staudinger ligation suffered from slow kinetics and easily 
oxidized phosphine reagents during the reaction process, thus making the reaction not a perfect 
candidate for glycan analysis and detection.31  
The most popular and common bioorthogonal method is copper-catalyzed click 
chemistry.28,32 This is a copper- catalyzed cycloaddition between alkyne and azide to form a 5 
membered ring.33 In early 2000’s, Sharpless group and Meldel group discovered that this reaction 
could be accelerated by copper dramatically, and this reaction can take place in an aqueous 
system.27,31 This copper- catalyzed azide-alkyne cycloaddition (CuAAC) is used widely in 
chemical biology, cell biology, cell surface glycan analysis and detection. This reaction being very 
simple and easy to perform it is widely been used by researchers both in industry and academia. 
During our study, we found most satisfying results with the click reactions and we adopted this 
chemistry for all our future work. 
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Figure 1.2 Copper-Catalyzed Click Chemistry (CuAAC) 
1.1.2 PCR 
 Another important part of our study is PCR, which is highly essential for the detection of 
DNA that is coupled with glycan which in turn symbolizes the glycan presence. The advent of the 
Polymerase Chain Reaction (PCR) radically transformed biological science from the time it was 
first discovered by Mullis in 1990. PCR based strategies have propelled huge scientific endeavors 
such as Human Genome Project. The technique is currently used by clinicians and researchers to 
diagnose diseases, clone and sequence genes, and carry out sophisticated quantitative and genomic 
studies in rapid and very sensitive manner. One of the most important medical applications of PCR 
method is the detection of pathogens. In addition, it is also widely used in forensics for the 
identification of criminals.46  
PCR can be performed using source DNA from a variety of tissues and organisms, 
including peripheral blood, skin, hair, saliva, and microbes. Only trace amounts of DNA are 
needed for PCR to generate enough copies to be analyzed using conventional laboratory methods. 
For this reason, PCR is a sensitive assay. Each PCR assay requires the presence of template DNA, 
primers, nucleotides, and DNA polymerase. The DNA polymerase is the key enzyme that links 
individual nucleotides together to form the PCR product. The nucleotides include the four bases – 
adenine, thymine, cytosine, and guanine (A, T, C, G) – that are found in DNA. These act as the 
building blocks that are used by the DNA polymerase to create the resultant PCR product. The 
primers in the reaction specify the exact DNA product to be amplified. The primers are short DNA 
fragments with a defined sequence complementary to the target DNA that is to be detected and 
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amplified. These serve as an extension point for the DNA polymerase to build on. The above-
mentioned components are mixed in a test tube or 96-well plate and then placed in a thermal cycler 
that allows repeated cycles of DNA amplification to occur in three basic steps. The reaction 
solution is first heated above the melting point of the two complementary DNA strands of the 
target DNA, which allows the strands to separate, a process called denaturation. The temperature 
is then lowered to allow the specific primers to bind to the target DNA segments, a process known 
as hybridization or annealing. Annealing between primers and the target DNA occurs only if they 
are complementary in sequence (e.g. A binding to G). The temperature is raised again, at which 
time the DNA polymerase is able to extend the primers by adding nucleotides to the developing 
DNA strand. With each repetition of these three steps, the number of copied DNA molecules 
increases exponentially.46 The PCR product is analyzed using agarose gel electrophoresis, which 
separates the DNA product based on the size and charge. The two main methods used for 
visualization of DNA are staining the product using ethidium bromide dye, which intercalates 
between the two strands of the DNA. However, due to the prevailing carcinogenic and serious 
health effects of ethidium bromide, it’s use has been reduced and replaced by SYBR™, a safe 
DNA gel stain. 
 
Figure 1.3 Key Components Of PCR 
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1) Denaturation: the reaction is heated to 95oC-98oC for 20-30 secs to break the hydrogen bonds; 2) 
Annealing: The reaction temperature is lowered to 50oC- 65oC for 20-40 secs (preferably 2oC-4oC less than 
the Tm of primers) to allow the primers to anneal to the template strands; 3) Elongation: The temperature 
is increased (optimum temperature of DNA polymerase preferably 72oC-78oC) to allow the addition of 
dNTP’s. At end of each cycle, the target sequence is doubled. 
 
The next generation advancement of the PCR technology was the development of RT-
qPCR. While in end point, PCR requires that PCR products were detected and quantified by gel 
electrophoresis after completion of the reaction, real-time qPCR technology allows quantification 
of PCR products in “real time” during each PCR cycle, yielding a quantitative measurement of 
PCR products accumulated during the course of the reaction. Real-time reactions are carried out 
in a thermocycler that permits measurement of a fluorescent detector molecule, which decreases 
post-processing steps and minimizes experimental error. This is most commonly achieved through 
the use of fluorescence based technologies. Three main fluorescence based technologies are, probe 
sequences that fluoresce upon (i) hydrolysis (TaqMan; Applied Biosystems, Foster City, CA, 
USA) or hybridization (LightCycler; Roche, Indianapolis, IN, USA); (ii) fluorescent hairpins; or 
(iii) intercalating dyes (SYBR Green). As SYBR™ Green binding is not specific for a target 
sequence this system can be readily used for different gene assays, is flexible, inexpensive, and 
accurate results can be obtained provided validation of the specificity by melt curve (or 
dissociation curve) analysis. The TaqMan™ chemistry is more expensive than DNA binding dye 
assays, but the presence of the hydrolysis probe ensures that only specific amplicons are measured. 
In addition, multiplexing reactions are possible, although their set-up requires an important 
optimization phase.47,48 
In brief, similar to end-point PCR, qPCR consists a succession of amplification cycles in 
which the template nucleic acid is denatured, annealed with specific oligonucleotide primers, and 
extended to generate a complementary strand using a thermostable DNA polymerase. This results 
in an exponential increase of amplicons (amplification products) that, in contrast with end-point 
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PCR, can be monitored at every cycle (in real time) using a fluorescent reporter. The increase in 
fluorescence is plotted against the cycle number to generate the amplification curve, from which a 
quantification cycle Cq (often described as Ct for cycle threshold) value can be determined. Cq 
corresponds to the number of cycles for which the amount of fluorescence (hence, of the template) 
is significantly higher than the background fluorescence. Therefore, the Cq value can be linked to 
the initial concentration of target nucleic acid and serves as a basis for absolute or relative template 
quantification. All steps of (RT-)qPCR may introduce experimental errors. qPCR is a robust 
technique, but due to its high sensitivity, very small variations can induce non-negligible 
differences in the results. To measure intra-assay variability, which follows a statistical 
distribution, RT-qPCR can be performed in triplicate (experimental replicates). Inter-assay 
variability can be estimated using a “reference” sample that will be included in each experiment.48  
 
Figure 1.4 Phases of qPCR. 
The PCR process goes through three main phases as the number of cycles and the amount of product 
generated increase. Initially, when the amount of product is small and enzyme and reagents are not limiting, 
product generation is exponential and the reaction is closest to 100% efficiency. This exponential growth 
is hard to detect initially through real-time fluorescence because the amount of product is small. During 
the linear phase, products continue to accumulate, but the reaction efficiency begins to fall and reagents 
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become limiting. Finally, in the plateau phase of the reaction, accumulation of product ceases as the 
reaction is exhausted for a number of different reasons.47 
For overall method development we adopted two systems, initially, we used the most 
known blood glycan antibody system (ABO) for the early stage method optimizations and, later 
we used the Globo-series glycan analogs as a small DNA encoded library for the proof of principle 
demonstration via detecting the breast cancer from patient plasma. 
1.1.3 ABO Blood Group System 
The discovery of the ABO blood group, over 100 years ago, caused great excitement. Until 
then, all blood had been assumed to be the same, and the often-tragic consequences of blood 
transfusions were not understood. The modern basis of the ABO blood group system was coined 
by Karl Landsteiner in 1900 when he discovered that the blood group of certain people 
agglutinated red cells present in other individuals.34 Ever since it has been studied extensively and 
well characterized with the structures of antigens and antibodies involved. The terminal 
carbohydrate structures present on the red blood cells and their antibodies present in the blood 
plasma determine the blood group. 
The ABO blood group antigens remain of prime importance in transfusion medicine— they 
are the most immunogenic of all the blood group antigens. The ABO blood group antigens also 
appear to have been important throughout our evolution because the frequencies of different ABO 
blood types vary among different populations, suggesting that a particular blood type conferred a 
selection advantage (e.g., resistance against an infectious disease.) 
The ABO blood group antigens are encoded by one genetic locus, the ABO locus, which 
has three alternative (allelic) forms—A, B, and O. A child receives one of the three alleles from 
each parent, giving rise to six possible genotypes and four possible blood types (phenotypes).  
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Table 1.1 Possible Blood types in offsprings 
 ABO Alleles Inherited from Mother 
ABO Alleles 
Inherited from 
Father 
 A B O 
A A AB A 
B AB B B 
O A B O 
The four basic ABO phenotypes are O, A, B, and AB. After it was found that blood group 
A RBCs reacted differently to a particular antibody (later called anti-A1), the blood group was 
divided into two phenotypes, A1 and A2. RBCs with the A1 phenotype react with anti-A1 and 
makeup about 80% of blood type A. RBCs with the A2 phenotype do not react with anti-A1 and 
they make up about 20% of blood type A. A1 red cells express about 5 times more A antigen than 
A2 red cells, but both types of red cell react with anti-A, and A1 and A2 blood groups are 
interchangeable. 
The immune system forms antibodies against whichever ABO blood group antigens are 
not found on the individual's RBCs. Thus, a group A individual will have anti-B antibodies and a 
group B individual will have anti-A antibodies. Blood group O is common, and individuals with 
this blood type will have both anti-A and anti-B in their serum. Blood group AB is the least 
common, and these individuals will have neither anti-A nor anti-B in their serum. 
Table 1.2 Antibodies and Antigen present in ABO Blood Typing System 
 
RBC of 
different blood 
group 
   
 
Antibodies in 
Serum 
  
None 
 
Antigen in RBC 
surface 
A B A and B None 
Genotype AO or AA BO or BB AB OO 
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The ABO locus is located on chromosome 9 has three main allelic forms: A, B, and O. The 
A allele encodes for a glycosyltransferase that produces the A antigen (N-acetylgalactosamine is 
its immunodominant sugar), and the B allele encodes for a glycosyltransferase that creates the B 
antigen (D-galactose is its immunodominant sugar). The O allele encodes for an enzyme with no 
function, and therefore neither A or B antigen is produced, leaving the underlying precursor (the 
H antigen) unchanged. These antigens are incorporated into one of four types of oligosaccharide 
chain, type 2 being the most common in the antigen-carrying molecules in RBC membranes. 
 
Figure 1.5 ABO Blood antigen structures. 
For A/B antigen synthesis to occur, a precursor called the H antigen must be present. In 
RBCs, the enzyme that synthesizes the H antigen is encoded by the H locus (FUT1). In saliva and 
other bodily secretions, the enzyme that synthesizes the H antigen is encoded by the Se locus 
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(FUT2). The H locus is located on chromosome 19 and it encodes a fucosyltransferase that 
produces the H antigen on RBCs.49  
Table 1.3 Distribution of various Blood Groups among Population 
Population Blood 
Group 
‘O’ 
Blood 
Group 
‘A1’ 
Blood 
Group 
‘A2’ 
Blood 
Group 
‘B” 
Blood 
Group 
‘A1B’ 
Blood 
Group 
‘A2B’ 
Caucasians 44% 33% 10% 9% 3% 1% 
Africans 49% 19% 8% 20% 3% 1% 
Asians 43% 27% Rare 25% 5% Rare 
 
1.1.4  Globo-H 
Similarly, eukaryotic cells are covered by a glycocalyx: an extensive network of 
polysaccharides. The glycocalyx serves as a rich source of binding sites for receptors and ligands, 
as well as pathogens and toxins. The mammalian glycome is estimated to consist of a few hundred 
unique glycan structures on glycoproteins and glycolipids. One such glycan is Globo H.50 
Some of the Globo-series glycans are overexpressed in certain cancers and are proven as 
biomarkers for early detection of breast cancer and ovarian cancer.7,35-37 Recent developments in 
the Globo-H immunotherapy also needs high sensitive methods to quantitatively detect the 
antiglobo-H antibodies for monitoring the therapy and in clinical trials.38-40   
Globo H is a glycosphingolipid of the Globo series with a sugar terminus resembling the 
blood group antigen H determinant. First identified in human teratocarcinoma and breast cancer 
cells, Globo H was found to be overexpressed on the cell surface of several epithelial cancers such 
as breast, colon, endometrial, gastric, pancreatic, lung, and prostate cancers. It is also moderately 
expressed in normal epithelial tissues (lung, breast, prostate, stomach, pancreas, and ovary), but 
its distribution is restricted to apical epithelial cells at lumen borders.36 In breast cancer Globo H 
expression was observed in >60% of ductal, lobular, and tubular carcinoma, but not in 
nonepithelial breast tumors. Globo H is not expressed in normal tissue except for weak expression 
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in the apical epithelial cells at lumen borders, a site that appears to be inaccessible to the immune 
system. Thus, Globo H has been considered as an ideal target for immunotherapy of many 
epithelial cancers and indeed two phase I trials of a Globo H-based vaccine in breast and prostate 
cancer, respectively, have shown promising results.45 
Functionally, Globo H has been associated with tumor stem cells, to be a potent inducer of 
angiogenesis, and an immunosuppressor through Notch signaling. The high Globo H expression 
by only cancer and cancer stem cells made it an attractive target for the generation of therapeutic 
cancer vaccines. These vaccines underwent the long history of development and improvement and 
are currently being tested in clinical trials for treatment. Globo H has therefore been considered as 
one promising tumor associated glycan biomarker, in particular for breast cancer.36 
 
 
Figure 1.6 Globo-H Structure 
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2 EXPERIMENT 
2.1 Systematic Coding of Sugars 
The first aim was to develop a unique coding method that is consistent with the 
representation of glycans, so it can be used in future for any DEGL with ease and without any 
uncertainty in future glycomics. Unlike peptides, proteins and DNA/RNA, representation of 
carbohydrate brings many challenges. A detailed representation should feature composition, 
sequence, branching position, modifications, and anomeric configuration. The use of symbols to 
represent the glycans was first proposed by Kornfield et.al.41 This approach has replaced the use 
of IUPAC naming for representation of glycan, with modifications adapted timely to fit the entire 
glycome.42-43 All these representations are based on symbols and color codes to represent the 
building blocks.  
Table 2.1 Glycan Representation (CFG) 
Symbolic Representation (Cartoon Representation 
CFG) 
IUPAC Naming (Linear Code) 
 
GalNAc b1-4 (Fuc a1-2) GlcNAc b1-
4 Man a1-3 (GalNAc b1-4 (Fuc a1-2) 
GlcNAc b1-4 Man a1-6) Man b1-
4 GlcNAc b1-4 (Fuc a1-6) GlcNAc 
 
With the above approach, it is pragmatic to use nucleotide bases to represent the glycans. 
But this also brings prevailing challenges for using nucleotide bases for glycans as there are many 
symbols and color codes are available for representation, but there are only 4 nucleotides bases A, 
T, G, and C are available for coding. To have enough nucleotide codes to cover the entire the 
glycome we had to depend on permutation and combination approach.  There are many sugar 
monomers which are incorporated in many ways in a glycan, making glycan structural information 
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very complex. These inherit difficulties lead to the development of a dedicated computer program, 
which can manage the structural information of the glycan to coding dictionaries and transform 
the IUPAC name of glycan to single stranded DNA code. For easy acceptance of the codes, the 
codes should be of minimal length storing all the glycan information and enable both PCR and 
qPCR amplification. 
For a perfect structure based coding, there must be a controlled vocabulary for all the 
structural components. For attaining this goal, the structural components of the carbohydrate were 
split into the structural components monosaccharides, linkages, and modifications etc. Three 
independent libraries were generated namely library A for monomer, library B for linkage and 
library C for modification. Next, all the monomers were gathered in library A and assigned each 
one with unique four-letter code. There are about 256 combinations generated using A, T, G, and 
C. About 70 monomers are added to this library as of now using the randomly generated codes. In 
a similar way, all possible linkages were accounted for library B, using codes based on 3 letters. 
Currently, there are 36 linkages in this library. For library C about 100 modifications were 
identified and incorporated in the library C and assigned with 4 letter codes which were not used 
in the library A. Special characters like ‘(` in the IUPAC naming for branching were assigned 
special codes. All these libraries were then incorporated into a Python-based program and the 
program was tested for about 100 glycans, for which the program successfully delivered the codes. 
The libraries can be extended and modified for addition as and when needed, to make this program 
a universal one and available for research community.  
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Table 2.2 Glycan Representation with DNA Codes 
Symbolic Representation (Cartoon 
Representation CFG) 
IUPAC Naming 
(Linear Code) 
DNA Code 
obtained through 
the program 
 
GalNAc b1-4 (Fuc a1-
2) GlcNAc b1-4 
Man a1-3 
(GalNAc b1-4 
(Fuc a1-2) 
GlcNAc b1-4 Man a1-
6) Man b1-
4 GlcNAc b1-4 
(Fuc a1-6) GlcNAc 
ACGCTGTTTT
AGAAAAGAA
AAAGCTGTAA
TAAACTTTAC
GCTGTTTTAG
AAAAGAAAA
AGCTGTAATA
ACAAAAAAT
ATGTAAGCTG
TTTTAGAAAC
AAAAAAGC 
 
 A sequence length between 50 -100 is best for PCR applications. Among 100 glycans 
tested most fell within this limit, but some exceeded this. Through careful observation of the 
sample library, there were many repeating fragments in the glycans (e.g. Six sugar core of N-
glycans). Hence, by taking this as a single block would reduce the length overall length of the 
codes of the long glycans, so a fourth library (Library D) was included in the program containing 
most of the common building blocks found in the glycans. Similar to other libraries, library D can 
also be extended, so as to cover the entire glycome and make it a universal one. 
Table 2.3 Long and Short DNA codes of the Glycan 
IUPAC Naming (Linear 
Code) 
Long DNA Code obtained through 
the program 
Short DNA Code 
obtained through the 
program 
GalNAc b1-4 (Fuc a1-
2) GlcNAc b1-4 Man a1-3 
(GalNAc b1-4 (Fuc a1-2) 
GlcNAc b1-4 Man a1-6) 
Man b1-4 GlcNAc b1-4 
(Fuc a1-6) GlcNAc 
ACGCTGTTTTAGAAAAGAAA
AAGCTGTAATAAACTTTACG
CTGTTTTAGAAAAGAAAAAG
CTGTAATAACAAAAAATATG
TAAGCTGTTTTAGAAACAAA
AAAGC 
Length – 105 
ACGCTGTTTTAGAAA
AGAAAAAGCTGTAA
TAAACTTTACGCTGT
TTTAGAAAAGAAAA
AGCTGTAATAACAA
AAGTACA 
Length - 79 
 
Another probable issue encountered was with short glycans, which gives small codes of 
length less than 25. This will face practical difficulty while doing qPCR. To resolve this issue a 
random DNA sequence of length 20 was added to the code with a mention in the program to avoid 
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the misreading. These two modifications made sure to keep the sequences within the desired limits 
to be used in the qPCR. 
Table 2.4 DNA code for short glycans 
IUPAC Naming (Linear 
Code) 
DNA Code obtained through 
the program 
Expanded DNA Code 
obtained through the 
program 
Rha ATAG 
Length – 4 
 
ATAGCCCCAGTCAGGC
CTAACGTA 
Length - 24 
2.2 Coding and Decoding of glycans through Program  
2.2.1 Coding  
For getting nucleotide sequence, glycan sequence is given in the input box with spaces in 
between each character of the glycan sequence. When a glycan sequence is inputted the program 
looks for each character from left to right. It checks for match in monomer dictionary (Library A), 
linkage dictionary (Library B) and modification dictionary (Library C). If a match is found, the 
corresponding nucleotide is placed under the name ‘nuc’. 
If the length of the nucleotide is less than 20, then an R nucleotide sequence is added to the 
‘nuc’ to increase the length the nucleotide sequence and output is published.  
If length of ‘nuc’ is more than 20 then the whole length of ‘nuc’ is searched for any 
matching sequences in the core dictionary (Library D). If there is match then a lengthy nucleotide 
core is replaced by a short 5 length sequence. This is done to reduce a lengthy nucleotide to short 
one for cost effectiveness. Reduced ‘nuc’ output is published.  
2.2.2 Decoding 
For decoding the nucleotide sequence back to glycan sequence, in the input box nucleotide 
sequence is given. The nucleotide sequence is searched for any matching five-length sequences in 
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the core dictionary (Library D). If there is any matching sequence then the length of nucleotide is 
extended to the original lengthy nucleotide sequence.  
 
Figure 2.1 Flowchart describing Coding 
 
If length of nucleotide is more than 0; first four nucleotide sequence are taken and match 
is found in the carb dictionary (Library A) and corresponding carb is taken for the output. Next 
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three nucleotide sequences are taken and searched for a match in linkage dictionary (Library B); 
if there are no match then next four nucleotides are taken and searched in modification dictionary 
(Library C) and next three nucleotides are again searched for a match in linkage dictionary (Library 
C). Then next three nucleotides are taken and seen if it is ‘AAA’ or ‘TTT’, if it is so then a 
corresponding branching is taken for output. Then next three nucleotides are taken and seen if it is 
‘AAA’ or ‘TTT’, if it is so then a corresponding branching is taken for output. This is done to 
cover the double branching cases. This continues for the complete length of the nucleotide 
sequence, before publishing the output. 
 
Figure 2.2 Flowchart describing decoding 
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Figure 2.3 CFG representation and DNA code for blood antigen A 
2.3 Materials 
All chemicals and biological reagents were purchased from Thermo Fisher unless 
otherwise mentioned. Maxima SYBR Green/ROX qPCR Master Mix, Platinum Pfx DNA 
Polymerase were purchased from Life Technologies (Carlsbad, CA). Micro Bio-Gel P-30 
Chromatography Columns were purchased from Bio-Rad (Hercules, CA). Tris[(1-Benzyl-1H-
1,2,3-Triazol-4-yl) methyl] amine (TBTA) Click chemistry Ligand were purchased from TCl 
(Tokyo, Japan). MicroAmp 96 well Fast PCR Reaction Plate, MicroAmp Optical Adhesive Film, 
MicroAmp Fast Reaction Tubes, Strips were purchased from Applied Biosystems (Foster City, 
CA). All oligonucleotides were purchased from Integrated DNA Technologies (Coralville, IA). 
Blood Group A Antigen-Antibody HE-193 (MA1-19693), Blood Group B Antigen-Antibody 
HEB-29 (MA1-19691) and Blood Group ABH Antigen-Antibody HE-10 (MA1-19694) were 
purchased from Thermo Fisher. 
2.4 Gradient PCR and Tm Determination 
 Gradient PCR was performed to figure out the optimal melting temperature to be used in 
the further quantitation experiments. Platinum Pfx DNA Polymerase was used for the PCR, 
approximately 26 µg of template, 1 µL of primers (10 µM), 1mM dNTP, 10X amplifying buffer, 
MgSO4, Polymerase and nuclease free water was used for a typical 25 µL reaction. Standard 
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thermocycling condition were used with different temperature during annealing phase of the cycle 
(95°C for 10 min, X°C for 30s, 95°C for 15s, 13 cycles) wherein X represents the annealing phase 
and temperature gradient from 50 oC - 60 oC were tested during this phase. The amplified PCR 
products were analyzed using 4% agarose gel electrophoresis. Tm determined using this method 
was used for qPCR.  
Table 2.5 Reaction mix for gradient PCR 
Component 25 uL  50 uL Final 
Concentration 
10X Amplifying 
Buffer 
5 uL 10 uL - 
MgSO4 1 uL 2 uL - 
dNTP(10mM) 0.75 uL 1.5 uL 0.3mM 
Forward 
Primer(10uM) 
0.75 uL 1.5 uL 0.3uM 
Reverse 
Primer(10uM) 
0.75 uL 1.5 uL 0.3uM 
Template(1uM) 1 uL 2 uL 0.04 
Polymerase 0.3 uL 0.5 uL - 
Nuclease-Free Water 15.4 uL 31 uL - 
2.5 Synthesis of Glycan(Antigen) – DNA Conjugates 
Glycan(Antigen)- DNA Conjugates were synthesized using Azido-Alkyne cycloaddition 
click reaction. The 5’-/5Hexynyl-terminated DNA was procured from the commercial suppliers 
(IDT) with standard desalting purified. All glycans were synthesized via chemo enzymatic method 
with the azido propyl linker at the reducing end. 
2.5.1 Click reaction procedure  
5’-Hexynyl-terminated DNA (500µM,20 µL, final concentration of 50 µM), azido glycan 
(500µM, 30 µL, final concentration of 75µM), 2M TEA buffer (pH 7, 20 µL, final concentration 
of 0.2M), 5 mM of freshly prepared Ascorbic acid solution (20 µL, final concentration 0.5mM), 
10 mM of copper-TBTA in 55% DMSO (10 µl, final concentration 0.5 mM) and 50 % volume 
DMSO (100 µL) were mixed together in a tube. The reaction mixture was vortexed and kept at 
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room temperature for overnight. The reaction mixture was purified using Micro Bio-Gel P-30 
Chromatography Columns (20 base pair cut-off). The concentration of the Glycan (Antigen)-DNA 
Conjugates was determined by absorbance at 260/280 using Nanodrop (ThermoFisher).  
 
 
 
Figure 2.4 Click Conjugation of 5’-Hexynyl DNA and azido modified glycans 
2.6 General protocol for qPCR  
2.6.1 For a typical 12.5 µL reaction  
The glycan(Antigen)- DNA Conjugates were added to 6.25 µL 2X Maxima SYBR Green/ 
ROX qPCR Master Mix with 1 µL primers (Forward Primer – 500 nm and Reverse Primer- 300 
nm). qPCR was performed with Applied Biosystems Stepone System (50 oC for 2 mins (Holding), 
95oC for 10 mins (Holding), 95 oC for 15 s, 60oC for 10 s, 72 OC for 10 s for 40 cycles). 
Ct or threshold cycle is a measurement of signal intensity for qPCR experiments. In a qPCR 
experiment, PCR is performed in presence of a fluorogenic intercalating dye (SYBR Green in our 
case). The dye intercalates with double-stranded DNA, as more double-stranded DNA is produced 
in each PCR cycle the dye increases the fluorescence intensity. Once the fluorescence intensity 
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reaches a threshold level, the cycle number is recorded by the instrument as Ct value. Therefore, 
sample having a large amount of DNA will have a lower Ct value compared to those samples 
containing relatively less amount of DNA. 
Table 2.6 Reaction mix for qPCR 
Component Volume (in uL) 
2x Maxima SYBR Green/ROX qPCR 
Master Mix  
6.25 
Forward Primer(500nm) 1 
Reverse Primer(300nm) 1 
Template (Gradient as stated above) 1 
Nuclease Free Water 3.25 
2.7 Filtration of Antibody-Antigen DNA Conjugates 
10 µL of glycan(antigen)-DNA Conjugate (5 µM) was incubated with 2 µL of antibody (if 
plasma is used then 2 µL of plasma is diluted to 8 µL using water) for 2 hours at room temperature. 
After two hours, the reaction volume was made up to 100 µL using TBST buffer. The reaction 
solution was washed using 100 µL TBST buffer for 7 times in 100kda cutoff centrifugation 
filtration filter tubes at 5000g for 10 mins. After washing the filtered and concentrated solution 
was used as a template for qPCR analysis.  
2.8 Immunoprecipitation of Antibody-Antigen-DNA Conjugates 
10 µL of glycan(antigen)- DNA Conjugate (5 µM) was incubated with 2 µL of antibody 
(if plasma is used then 2 µL of plasma is diluted to 8 µL using water) for 2 hours at room 
temperature. After two hours, the reaction volume was made up to 100 µL using TBST buffer and 
added to 20 µL of prewashed A/G protein bead and incubated for one hour at room temperature 
with occasional shaking at an interval of 15 mins. After one hour, the beads were washed 
thoroughly for 7 times using TBST buffer. After washing the beads were reconstituted in 20 µL of 
TBST buffer. The beads were directly used a template for qPCR analysis. 
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2.9 Blood Collection 
Blood was collected from 10 volunteers by finger pricking, and collected to heparin-coated 
blood collection tubes. The collected blood was centrifuged at 5000 rpm for about 5 mins for 
obtaining plasma from blood. The collected plasma is stored at -20oC until use.  
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3 RESULTS AND DISSCUSSION 
In this study, I have developed a program which can generate DNA code specifically for 
each glycan (described in systematic coding of sugars under experimental section). Next steps 
were to successfully couple DNA and glycan using click chemistry, develop methods for glycan 
and protein binding, and analyze the glycan using qPCR.  
3.1 DNA sequences  
Using the developed Python-based program DNA sequences for blood group antigens and 
Globo glycan series were obtained.   
Table 3.1 DNA sequences 
 For all 5’ to 3’ DNA Sequences BOLD is the forward primer and BOLD ITALIC is the reverse primer 
binding site. 
 
Name 5’Mod Sequence 3’Mod 
O DNA 5Hexynyl AATGATACGGCGACCACCGAAGAAAAGACGATCTAAGCTCT
ACGATGTAAGACACGTCTGAACTCCAGTCAC 
None 
A DNA 5Hexynyl AATGATACGGCGACCACCGAACGCAACTTTAGAAAAGAAAA
CGATCTAAGATCTACGATGTAACACGTCTGAACTCCAGTCAC 
None 
B DNA 5Hexynyl AATGATACGGCGACCACCGAACGAAACTTTAGAAAAGAAAA
CGATCTAAGCTCTACGATGTAAGACACGTCTGAACTCCAGTCAC 
None 
Gb-H 5Hexynyl AATGATACGGCGACCACCGAAAGAAAAGACGATCTACGCTC
TACGAATAACGATGTAAGACACGTCTGAACTCCAGTCAC  
None 
Gb-5 5Hexynyl AATGATACGGCGACCACCGAAACGATCTACGCTCTACGAATA
ACGATGTAAGA CACGTCTGAACTCCAGTCAC 
None 
Gb-4 5Hexynyl AATGATACGGCGACCACCGAACGCTCTACGAATAACGATGTA
AGACACGTCTGAACTCCAGTCAC 
None 
Gb-3 5Hexynyl AATGATACGGCGACCACCGAAACGAATAACGATGTAAGACC
CCAGTCAGGCCTAACGTACACGTCTGAACTCCAGTCAC 
None 
 Gb-2 5Hexynyl AATGATACGGCGACCACCGAAACGATGTAAGACCCCAGTCA
GGCCTAACGTA CACGTCTGAACTCCAGTCAC 
None 
Bb-4 5Hexynyl AATGATACGGCGACCACCGAAAGAAAAGACGATCTACGCTC
TACGACACGTCTGAACTCCAGTCAC 
None 
Bb-3 5Hexynyl AATGATACGGCGACCACCGAAAGAAAAGACGATCTACGCCC
CCAGTCAGGCCTAACGTACACGTCTGAACTCCAGTCAC 
None 
Bb-2 5Hexynyl AATGATACGGCGACCACCGAAAGAAAAGACGACCCCAGTCA
GGCCTAACGTACACGTCTGAACTCCAGTCAC 
None 
FW Primer None AATGATACGGCGACCACCGAA None 
RV Primer None GTGACTGGAGTTCAGACGTG 
 
 
 
 
 
None 
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The obtained DNA sequences were flanked with primer binding domains and 5’ Hexynyl 
modification were procured from IDT. 
3.2 Tm Determination 
Tm was determined using the protocol for gradient PCR and Tm Determination (under 
experimental section) for further quantitation experiments. After PCR to determine the optimum 
temperature the PCR products were analyzed in using 4% agarose gel. 
 
                                                        
Figure 3.1 Tm Determination 
Gel analysis of the PCR product (Figure 3.1) showed the optimum temperature to be in a 
range of 52oC-60oC. 60oC was used as annealing temperature for further experiments.  
3.3 Glycan (Antigen) – DNA Conjugates 
After Tm determination, the 5’-Hexynyl terminated DNA and azido glycan were coupled 
together using click chemistry according to the protocol mentioned under synthesis of 
Glycan(Antigen) – DNA Conjugates (under experimental section). 
A PCR comparison was conducted between pure DNA and G+DNA to make sure that the 
DNA can be used for further PCR reaction after conjugation with glycan. PCR was conducted 
29 
under the same conditions as stated under Gradient PCR and Tm Determination and analyzed using 
4% agarose gel electrophoresis. 
 
Figure 3.2 PCR Comparison of DNA_A and G+DNA_A 
From the gel analysis of the PCR product (Figure 3.2) a clear concrete band was visible in 
both DNA and G+DNA, which made sure that the DNA can be used for the further analysis after 
conjugation with the glycan. 
To make sure that the Glycan-DNA conjugate can be used for binding the protein with the 
glycan and DNA can be used for PCR analysis, any presence of residual unreacted DNA was 
further tested by PCR amplification and gel electrophoresis. Pure DNA_A and G+DNA_A was 
incubated with the specific antibody for two hours and washed with the washing buffer, and later 
eluted with the elution buffer. Both wash and elution buffers were collected and performed a PCR. 
Gel analysis of the PCR product (Figure 3.3) did not show a band in the wash buffer (residual 
unreacted DNA) but a strong band was seen in elution buffer indicating near perfect efficiency of 
coupling protocol. 
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Figure 3.3DNA and Glycan- DNA Conjugate IP Analysis 
3.4 qPCR Reactions and Standard Curve 
The success of DEGL lies in the readiness of applying the DNA codes to the standard PCR 
and qPCR protocols. It is important to have the glycan-coupled DNA (G+DNA) achieve similar 
PCR efficiency to the native DNA, so compared the G+DNA conjugates with the corresponding 
DNA strands to verify the efficiency of amplification in both PCR and qPCR. In all the above 
sections, PCR was performed on the both DNA and G+DNA using standard thermocycling with 
different annealing temperatures and Immunoprecipitation methods. Next, experiment was carried 
out to determine the qPCR detection limit of both pure DNA and G+DNA. Both pure DNA and 
G+DNA were serially diluted to provide different concentrations of templates, with final 
concentrations ranging from 2.4 nM to 16 pM. Standard curve qPCR was carried out to obtain the 
corresponding Ct values, Critical threshold value (Ct) is generally used to compare the 
concentration of the templates in the qPCR reaction mixture, a low Ct indicating high template 
concentration. Ct values of the conjugates from 2.4 nM to 16 pM concentrations were observed in 
the range of 5-25, while the negative control (no template control, NTC) gave a Ct value above 30 
(Figure 3.4). The test was not conducted for further low concentrations worrying about the 
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interference of primer dimer formation, a potential challenge in amplifying templates smaller than 
100 bases. Nevertheless, a standard plot of the Ct value vs log concentration of the DNA and 
G+DNA conjugate (Figure 3.5) did show the linear relation indicating the successful application 
of G+DNA for quantitative detection up to the picomolar level. Both DNA and DNA-Glycan 
conjugates gave similar amplification, assuring that the DNA tag can be an alternative to detect 
the glycan itself. Encouraged by the result clearly suggesting the detection of glycans from even a 
picomolar level, proceeded to the final goal, screening of glycans against glycan binding proteins. 
 
 
Figure 3.4 qPCR limit of detection comparison of glycan DNA conjugate and pure DNA  
A &C amplification plot and Ct value plot of glycan DNA conjugate; B & D amplification plot and Ct value 
plot of pure DNA 
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Figure 3.5 Standard Curve Plot  
A) Standard Curve plot of pure DNA; B) Standard Curve plot of Glycan DNA conjugate 
3.5 Blood Glycan – Antibody Sensitivity study: Filtration 
Since G+DNA could be applied in both screening and detection, DEGLs enable 
interrogation of the glycans against target proteins in solution, while known glycan-DNA 
interactions could be used to detect a specific target with high sensitivity.  Two set of experiments 
were done for validating these two aspects of DEGL; initially demonstrated the detection of 
specific glycan binding proteins by using the familiar blood glycan-antibody interactions. As a 
proof of principle study to demonstrate the significance of DNA Encoded Glycan Library (DEGL), 
the blood group antigen-antibody interactions were chosen.  
Structures of the O (or H), A, and B antigens are well known (Figure 3.6).  This system 
was selected for the study mainly due to two reasons, i) It is most studied and accepted among all 
the glycan interactions, and ii) They offer the opportunity to study both the sensitivity and 
specificity of the technique because of the structural similarities. Three blood group antigens A, B 
and O sugars were synthesized chemo-enzymatically. Synthesis of glycan-DNA conjugate was 
achieved via click chemistry.44 A, B and O glycans were coupled with the corresponding 5’ alkyne 
modified DNA (DNA code + Primers).  
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Figure 3.6 Blood Group ABO antigen- DNA conjugate structures 
All three G-DNA conjugates (G1+A DNA, G2+B DNA and G3+O DNA, with G1, G2 and 
G3 representing A, B, and O glycan antigens, respectively) were interrogated with the 
commercially-procured human blood antibodies (IgM, mouse). Concentrations of 5 µM, 2.5 µM, 
and 1 µM of the G+DNA were incubated with 2 µL of the antibodies; unbound DNA was 
eliminated by filtration with 100k cut off centrifuge tubes. The filtrate after incubating with the 
antibodies were subjected to qPCR assay, and Ct values of the G+DNA were compared with the 
Ct values of negative control where antibody was omitted from the incubation. A Ct difference of 
more than 10 points was observed at all three G+DNA concentrations indicating the requirement 
of low concentration of glycans for the accurate results. The filtration results were consistent with 
the concentration of antigens used, and were found to be more sensitive (Figure 3.7). The higher 
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sensitivity of the filtration method may have been due to the size difference of IgM antibodies and 
DNA strands (900 kDa and 25 kDa, respectively). From the above experiment, it was proven that 
DEGL can be used for detection of specific glycan binding proteins by using the familiar blood 
glycan-antibody interactions over a range of concentration (5 µM, 2.5 µM, 1 µM). With the success 
of above experiment, 2.5 µM was used for further demonstration of selectivity and specificity of 
the glycan binding proteins by using blood glycan-antibody interactions. 
Next aspect of DEGL is to screen for the glycan binding proteins and, for addressing this 
mixed all three antibodies (1:1:1) and interrogated this mixture with each of the G+DNA 
conjugates (2.5 uM) separately. 
As seen in figure 3.8a, Ct values of 8.4 and 7.7 respectively for G1+A DNA and G2+B 
DNA indicate the high affinity binding of A and B glycans with their corresponding antibodies 
Ab-A and Ab-B. But a similarly tested G3+O DNA showed relatively higher Ct value compared 
to both A and B conjugates but still less than that of the no antibody controls indicating weak 
interaction of antigens with the Ab-O. 
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Figure 3.7 Comparison of Filtration  
Sensitivity Study A) G1+A DNA against the antibody A at different concentrations (5 µM, 2.5 µM, 1 µM); 
B) G2+B DNA against the antibody B at different concentrations (5 µM, 2.5 µM, 1 µM); C) G3+O DNA 
against the antibody O at different concentrations (5 µM, 2.5 µM, 1 µM); D) Ct values plot for G+DNA at 
different concentrations (5 µM, 2.5 µM, 1 µM). 
 
This result indicates that DEGL could also work with many closely related target proteins 
around without any loss of selectivity. The specificity of the method was also tested, for this 
investigated a single G+DNA (G2+B DNA) against the three antibodies, a clear amplification was 
visible only when both Ab B and G2+B DNA were in the mix and all the remaining tests were 
poorly amplified. This result clearly indicates that the amplification is indeed from the target 
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specific binding of glycan and there is no significant interference of nonspecific binding of DNA 
and target proteins. 
 
Figure 3.8 Filtration study with G+DNA conjugates and Antibody  
A) G+DNA conjugates against the mixture of antibodies having equal concentration of Ab-A, Ab-B and 
Ab-O B) G2+B DNA against each antibody separately 
3.6 Blood Glycan – Antibody Interaction Comparison: Filtration and 
Immunoprecipitation 
The next step was to try with natural blood serum, for this blood was collected using finger 
pricking as stated in blood collection (under experimental section). Since the natural blood has IgG 
antibodies, a comparison between filtration and immunoprecipitation was conducted to find the 
best method. For interrogating this aspect G+DNA at concentration of 2.5 µM was incubated with 
2 µl of diluted plasma (2 µl of plasma was diluted with 8 µl water) with two different blood plasma 
(Blood Groups O and B). The unbound DNA was washed by both filtration and 
immunoprecipitation methods. The filtrate/eluent after incubating with the blood plasma (washed 
of unbound DNA) were subjected to qPCR assay, and Ct values of the G+DNA were compared 
with the Ct values of negative control where blood plasma was omitted from the incubation. A Ct 
difference of more than 10 points was observed at filtration results. The filtration results were 
consistent with the concentration of antigen used (figure 3.7), and were found to be more sensitive. 
The higher sensitivity of the filtration method may have been due to the size difference of IgM 
37 
antibodies and DNA strands (150 kDa and 25 kDa, respectively). A Ct difference of about 10 
points was observed at immunoprecipitation results. The immunoprecipitation was consistent with 
the concentration of antigen used, and was found to be more accurate and specific from the 
amplification curve (Figure 3.10). The higher accuracy and specificity of the immunoprecipitation 
may have been due to the compatibility of beads with the qPCR. Ct value of 20.3 in G1+A DNA 
and 22.2 in G2+B DNA (Immunoprecipitation) and Ct value of 4.5 in G1+A DNA and 6.8 in 
G2+B DNA (Filtration) was obtained with blood group B (Figure 3.9). 
 
Figure 3.9 Ct value comparison  
A) Ct value comparison Filtration; B) Ct value Comparison Immunoprecipitation 
Similarly, Ct value of 17.6 in G1+A DNA and 18.4 in G2+ B DNA (Immunoprecipitation) 
and Ct value of 4.9 in G1+A DNA and 4.8 in G2+B DNA (Filtration) was obtained with blood 
group O. A lower Ct value in G1+ A DNA with Blood Group B and almost same Ct value in G1+A 
DNA and G2+B DNA with Blood Group O proved this method can be used for inverse blood 
group typing. 
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Figure 3.10 Amplification plot comparison 
A) Amplification Plot Blood Group B Immunoprecipitation; B) Amplification Plot Blood Group O 
Immunoprecipitation; C) Amplification Plot Blood Group B Filtration; D) Amplification Plot Blood Group 
O Filtration. 
 
3.7 DEGL: Real Life experiments – Inverse Blood Typing  
From the successful results with two real blood experiments, blood typing experiments 
were conducted by collecting samples from healthy volunteers. Identifying the serum antibody 
present in the blood plasma will help to identify the blood group, person having the A antibodies 
alone in the blood have B antigen (group B), person with B antibodies alone are of A blood group, 
those who have both the antibodies belongs to the O and no antibodies in the blood indicating AB 
group (Table 3.2). This type of blood typing is called as inverse blood typing. However, the 
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conventional blood typing used widely is based on agglutination which is a direct blood typing 
using antigens (glycan antigen) on the surface of the RBC’s. 
Table 3.2 Blood Group Antigens and Antibodies 
 
 Few microliters of blood were collected from 10 healthy volunteers using a finger prick, 
collected blood were centrifuged to separate the plasma and cellular components. The blood 
plasma was used to detect the blood group, 4 uL of the plasma was diluted to 20 uL and from this 
2 uL each was incubated with A and B antibodies for 2 hours to allow the formation of G+DNA-
Ab complexes. Further, G+DNA-Ab complexes were allowed to interact with the protein A/G 
magnetic beads for 1 hour, separated using a magnetic stand and washed seven times to discard 
any unbound G+DNA. After thoroughly washing the G+DNA-Ab-Bead complex, it was diluted 
to 10 uL with water and 1 uL was directly used as a template in the qPCR. Ct values of the G+DNA 
in the blood plasma was compared with the Ct value of G+DNA with no plasma. Among the 10 
samples tested, two samples showed low Ct values for both G1+A DNA and G2+B DNA 
indicating the presence of both antibodies and hence belonged to O group. Five of the samples had 
a low Ct value for G2+B DNA means A group and three of the samples had a low Ct value for the 
RBC of different 
blood group 
   
 
Antibodies in 
Plasma 
  
 
 
DEGL 
(G1+A DNA, 
G2+B DNA)     
Results (Ct 
values) 
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G1+A DNA implying B group (Figure 3.11). All the results were accorded with the conventional 
blood typing. The above results indicated that the DEGL can be used for inverse blood typing, 
which can be an alternative for conventional blood typing. However, using this method the rhesus 
group cannot be diagnosed as it is a protein antigen-antibody interaction.  
 
Figure 3.11 Amplification plot and Ct Value comparison of Blood Typing 
3.8 Globo Series Library  
After the successful completion of library synthesis and qPCR method development using 
blood glycans and inverse blood typing, next the concept was applied to Globo glycans. Here 
DEGL and glyco-PCR were used to profile the Globo-glycan binding antibodies and there by 
detecting the cancers expressing these antigens. Globo-glycans are part of the glycosphingolipids 
and their expression pattern is well correlated with the cancer metastasis and progression. Aberrant 
expression of Globo-glycans will also prompt the body to generate the anti-glycan antibodies 
targeting these epitopes. These antibodies are generally observed in the sera even before the cancer 
progression to the late stages and effectively act as biomarkers for certain types of cancer including 
breast, lung, prostate and ovarian cancer.7,36,45  
B 
A 
O 
No Ab 
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                                 Figure 3.12 Globo glycan structures and Globo-glycan conjugates 
Globo-H and its truncated analogs Gb-5, Gb-4, Gb-3, and Gb-2 were synthesized from the 
enzymatic extension of chemically synthesized Gb-2. To test the terminal epitope specificity alone; 
Bb-4, Bb-3 and Bb-2 were also synthesized via chemo-enzymatic strategy.  
Initially, tested with the Globo-H glycan conjugate alone with the commercial anti Globo-
H human antibody VK-9 in the same way as with the blood glycans, and the results are shown in 
the figure 3.13. Two concentrations of Globo-H glycan-DNA conjugate (2.5 µM and 5 µM) were 
incubated with 2 µL of VK-9 antibody and compared the Ct value with the no antibody control 
experiments. As expected, the amplification and Ct values were correlated with the concentration 
of the antigens present in the solution, a low Ct value of 7 and 19 was observed for 5 µM conjugate 
and comparatively higher Ct value of 14 and 21 was obtained for 2.5 µM conjugate. 
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Figure 3.13 Amplification plot and Ct value Globo-H Vs VK-9 A) Amplification Plot and B) Ct Value 
plot 
3.9 Detection of glycan binding antibodies present in the cancer plasma 
After gaining the confidence from the Globo-H and VK-9 interrogation studies, we 
conducted an elaborate study using all the Globo series glycan against two breast cancer plasma 
samples (sanguine bioscience BC1 and BC2), and compared the Ct values of each glycan 
conjugates with the sample treated with both healthy serum (HS) and no serum (NS). The results 
show that only GbH, Bb4 and Bb3 had significant amplification with the Ct values less than 8, 
while other glycan conjugates show relatively less amplification (Figure 3.14 and 3.15). 
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Figure 3.14 Ct Value Plot of different Globo glycan conjugate series with breast cancer serum (BC1 and 
BC2), Healthy Serum (HS) and No Serum (NS). 
These results are consistent with the micro array based methods reported by Chi-Huey 
Wong group.7 Though this approach accurately differentiated the cancer plasma from the healthy 
plasma based on the presence of glycan binding antibodies, it is not convenient to test every glycan 
conjugate separately and it is not practical when several plasma samples are needed to be tested. 
But this difficulty can be easily overcome by employing next generation sequencing (NGS), which 
allow mixing of the glycan conjugate and mixing of plasma samples with one additional step of 
barcode indexing. Hence NGS technology allows the high throughput detection of hundreds of 
plasma samples with even thousands of glycans in the DEGL. 
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Figure 3.15 Amplification Plot of different Globo glycan conjugate series with breast cancer serum 
(BC1 and BC2), Healthy serum (HS) and No serum (NS) 
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4 CONCLUSION 
With the advancement of the technologies in the DNA synthesis and sequencing have 
brought the enormous potential of DNA in the applications beyond genetics. DNA encoded 
libraries (DEL) are of the modern concept in drug screening and lead optimization. This study 
recognized the importance of DEL technologies in the functional glycomics (DEGL), which is 
otherwise limited to the low sensitive detection techniques and highly difficult to obtain samples. 
Applying the highly sensitive qPCR detection will enhance the reach of functional glycomics to 
low nano gram samples and high throughput screening. Here a unique method has been described 
to code each glycan, accounting their structural information very similar to how proteins coded 
with triplet codons. The program which is available for the use of research community is aimed to 
provide and keep a uniformity in the codes for every single glycan in the future DEGL 
technologies.  
A strict library of DNA codes will not only reduce the confusion in the community but also 
bring down the synthetic expenses using optional bulk synthesis. Along with the unique DNA 
codes, it also produces an agreement on the coupling chemistry and primer selection to have the 
ready-made glycan codes for research use. Also identified copper assisted alkyne-azide coupling 
(CuAAC) chemistry, also known as ‘click chemistry’ for the best result in because most DNA 
suppliers readily offer azide and alkyne modifications on their library. 
In a proof of principle study, generated a small DEGL consisting the common blood 
antigens and their detection in solution were demonstrated. With the same principle did a blood 
group analysis with the DEGL to confirm the use of DEGL in detecting the glycan binding 
antibodies. Although inverse blood typing can’t replace the gold standard conventional direct 
blood typing based on the surface antigen, this study can be further extended to the next level 
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where the blood typing will be based on the analysis of P1PK, FORS, Se, Le and I blood glycan 
antigens. All the blood glycan antigens (ABO, P1PK, FORS, Se, Le and I) will form a complete 
blood glycan group typing. Some of them being highly rare antigens, this kind of analysis will 
make a place along with molecular blood typing and other rare antigen blood typing apart from 
the conventional ABO typing. 
Finally, another DEGL consisting the Globo glycan series was generated and their 
detection in solution and breast cancer serum were demonstrated to confirm the use of DEGL in 
detecting the glycan binding antibodies which are of highly significant in the diagnostic 
applications. Here, Globo-glycans were analyzed in cancer serum which can be extended to several 
other diseases like Crohn’s disease, Rheumatoid arthritis, cancers and infection where disease-
specific glycan biomarkers and determinants can be found. This application of DEGL can be 
promising for the analysis of disease-specific glycan biomarkers and determinants for early 
diagnosis of the disease.   
With the successful results from the proof of principle study namely inverse blood typing 
and detection of Globo-glycans in cancer samples, it has been proven that the DEGL will be an 
efficient method in future years to come. DEGL will find its own space along with other prevalent 
technologies available. 
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